Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Abbott GmbH & Co. KG
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
A Study of Two Different Adalimumab Formulations in Adults with Rheumatoid Arthritis
Compare the injection site related pain profile of two different formulations of Humira immediately after injection.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
The primary objective of this study is to compare the analgesic efficacy and the safety of ABT-894 (6 mg tablets) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pain (DNP).Additionally, this study will also explore the pharmacokinetic and pharmacogenetic characteristics of ABT-894 in the DNP population
The primary objective of this study is to compare the analgesic efficacy and the safety of ABT-894 (6 mg tablets) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pai...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) versus Efavirenz (EFV) plus TDF and FTC in Antiretroviral-Naïve HIV-1/HCV Co-infected Subjects
To assess the safety, tolerability, and antiviral activity of two treatment strategies in HIV-1/HCV co-infected subjects: -LPV/r-based induction/maintenance strategy; -EFV-based three-drug regimen.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO)
To demonstrate the safety of adalimumab in PsA patients in a normal clinical setting. The patients may be on concomitant NSAID(s), steroids, one or more DMARDs, either as single treatment or in combin...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors
To evaluate the safety and efficacy of paricalcitol capsules on albuminuria reduction in CKD subjects with Type 2 diabetic nephropathy receiving optimal ACEi and/or Angiotensin II-Receptor-Blocker the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
A double-blind, placebo-contolled study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 coadministered with Ribavirin (RBV) in people with hepatitis C virus (HCV) that have not been treated before. "Experimental" means that they have not been approved by any regulatory agency for sale to the public
The primary objectives of this study are to determine the SVR12 rate of 12 weeks of treatment with ABT-450/r/ABT-267 and ABT-333 co-administered with RBV and to assess the safety of the DAA combinatio...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
A Multicenter, Randomized, Double-blind, Placebo controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis
The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination with Topical Treatment (Calcipotriol/Betamethasone) in Subjects with Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)
To assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone vs. adalimumab in combination with matching vehicle in subjects with moderat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors
To evaluate adalimumab 40 mg eow sc in subjects with active AS in day-to-day clinical practice. The safety and efficacy of adalimumab will be analyzed based on concomitant NSAID use, concomitant stero...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Abbott GmbH & Co. KG
Update Il y a 4 ans
A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects with Diabetic Neuropathic Pain
To compare the analgesic efficacy and the safety of ABT-639 (100 mg capsules) administered twice daily to placebo in the treatment of diabetic neuropathic pain (DNP). Pregabalin 150 mg administered t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
Next